According to the above data, the selective agonists of the GABA-A receptor complex are the drugs of first choice in the drug treatment of insomnia. [22] Once treatment has started, monitoring and ...
Eisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Merck & Co’s Belsomra, which made its debut there in 2014. Dayvigo (lemborexant) is a dual ...
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Context: Fatal familial insomnia (FFI) is a genetically transmitted neurodegenerative prion disease that incurs great suffering and has neither a treatment nor a cure. The clinical literature is ...